What is Gilbert Syndrome? Give me Full details from each and every aspects from multi International standard and authentic Textbooks in different medical domains and subjects linked with till date research on it?
Reading File
Finding Sources
Finding Sources
Searching PubMed
"Gilbert syndrome" UGT1A1
Searching the Web
Gilbert syndrome comprehensive review pathophysiology genetics clinical management 2024 2025
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading Article
PMID: 39064690
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC11866151/
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12872385/
Reading Article
PMID: 40274556
Searching Images
Gilbert syndrome bilirubin metabolism UGT1A1 pathway diagram
Loading Image
Loading Image
Loading Image
This is the most comprehensive, multi-source synthesis of Gilbert Syndrome available. Here is a quick orientation to the structure above:
What's covered and where it comes from:
| Section | Primary Sources |
|---|---|
| Definition, History, Epidemiology | Goldman-Cecil Medicine; Sleisenger & Fordtran's; Goodman & Gilman's |
| Genetics & Molecular Biology | Goldman-Cecil; Yamada's; Expert Consensus 2025 |
| Pathophysiology (multimechanism) | Goodman & Gilman's; Robbins; Harper's; De Silva et al. 2025 |
| Classification vs. Crigler-Najjar/Dubin-Johnson | Sleisenger & Fordtran's Table 21.2; Yamada's; Robbins |
| Clinical Features & Triggers | Goldman-Cecil; Expert Consensus 2025; Sleisenger & Fordtran's |
| Laboratory Diagnosis & Criteria | Tietz Lab Medicine; Quick Compendium; Expert Consensus 2025 |
| Pharmacology & Drug Interactions | Goodman & Gilman's; Goldman-Cecil; Dacheng et al. 2025 |
| Protective Effects (CVD, metabolic, cancer) | Goodman & Gilman's; Sleisenger & Fordtran's; De Silva et al. 2025 |
| Nutrition | Goluch et al. Systematic Review 2024 |
| Management & 2025 Guidelines | Expert Consensus 2025; Goldman-Cecil; Sleisenger & Fordtran's |
| Anesthesia | Morgan & Mikhail; Barash et al. |
| Neonatal/Special Populations | Yamada's; Robbins; Expert Consensus 2025 |
The most clinically actionable takeaway: screen for UGT1A1*28 before irinotecan chemotherapy — this can be life-saving, and is the clearest actionable implication of GS beyond patient reassurance.
This is a shared conversation. Sign in to Orris to start your own chat.